S&P 500 Industrials Sector SEC Filings — February 26, 2026

27-02-2026

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced a proposed private placement of $200M aggregate principal amount of Convertible Senior Notes due 2032 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $30M within 13 days of issuance. Net proceeds will fund capped call transactions to offset potential dilution and general corporate purposes, including acquisitions, strategic investments, working capital, and capital expenditures. The offering is subject to market conditions, with terms like interest rate and conversion rate to be set at pricing; forward-looking statements highlight risks such as market changes and failure to close.

• ·Notes are general unsecured obligations accruing semiannual interest; conversion at Tandem's election into cash, shares, or combination.
• ·Capped call transactions with option counterparties to cover shares underlying the notes, subject to cap.
• ·Notes and conversion shares unregistered under Securities Act; no offer/sale without exemption.
• ·Announcement date: February 23, 2026; SEC filing date: February 27, 2026.
• ·Maturity: 2032; hedge modifications possible by counterparties through maturity.

27-02-2026

ANI Pharmaceuticals Inc filed an 8-K on February 27, 2026 (AccNo: 0001023024-26-000013), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics were explicitly stated in the provided filing details. This is a standard disclosure for financial results with no indicated positive or negative performance variations.

27-02-2026

Western New England Bancorp, Inc. announced on February 24, 2026, that Paul Picknelly, a member of its Board of Directors, will retire effective May 14, 2026, immediately following the 2026 Annual Meeting of Stockholders. Mr. Picknelly's decision was not due to any disagreement with the company's operations, policies, or practices. No other changes or financial impacts were disclosed.

27-02-2026

Verde Resources, Inc. filed a Form 8-K on February 27, 2026, reporting under Item 5.07 the submission of matters to a vote of security holders, likely related to a shareholder meeting. No specific matters, voting results, outcomes, or any quantitative data such as vote percentages, share counts, or financial implications are disclosed in the provided filing information. This appears to be a mandatory, single-item informational disclosure with no evident positive or negative metrics.

27-02-2026

Amneal Pharmaceuticals, Inc. filed an 8-K on February 27, 2026, disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific quantitative financial metrics, comparisons, positive or negative changes, or other details are provided in the filing information.

27-02-2026

Flutter Entertainment plc filed an 8-K on February 27, 2026 (AccNo: 0001193125-26-078977, Size: 139 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing discloses material information publicly to comply with Regulation FD, with exhibits attached, but specific content details are NOT_DISCLOSED. No financial metrics, transactions, or performance data (positive, negative, or flat) are mentioned.

27-02-2026

Golden Entertainment, Inc. filed a Form 8-K on February 27, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, or performance indicators (positive, negative, or flat) are disclosed in the provided filing details. This appears to be a standard earnings-related disclosure with no quantified impacts available.

27-02-2026

Escalade Inc filed an 8-K on February 27, 2026, under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information. This multi-item filing provides metadata on the earnings release but lacks detailed financial data for analysis.

27-02-2026

Bain Capital Specialty Finance, Inc. filed an 8-K on February 27, 2026, disclosing information under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, transaction details, or guidance are provided in the filing summary. This appears to be a multi-item voluntary or mandatory earnings-related disclosure, but quantitative impacts are NOT_DISCLOSED.

27-02-2026

Sunoco LP filed a Form 8-K on February 27, 2026, reporting under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing indicating voluntary disclosure of material information previously shared selectively with certain parties, with exhibits attached. No specific details, financial metrics, transactions, or performance data are disclosed.

27-02-2026

Graphic Packaging Holding Co filed an 8-K on 2026-02-27 disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, accompanied by financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific details on transaction terms, size, parties, or financial impacts provided in the available information. No quantitative metrics, positive or negative performance indicators, or period-over-period comparisons are mentioned.

27-02-2026

UWM Holdings Corp filed an 8-K on February 27, 2026 (AccNo: 0001783398-26-000018, size 3 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing with no specific details on the disclosed information, financial metrics, transactions, or exhibits provided. No quantitative data, period-over-period comparisons, or directional metrics are mentioned.

27-02-2026

Xeris Biopharma Holdings, Inc. filed an 8-K on 2026-02-27 reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely involving voluntary disclosure of material nonpublic information and attached exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the provided filing metadata.

27-02-2026

Anteris Technologies Global Corp. filed an 8-K on February 27, 2026 (AccNo: 0001140361-26-007003), reporting under Item 2.02 Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. This constitutes a multi-item voluntary disclosure of financial results. No specific revenue, earnings, balance sheet details, guidance, or quantitative metrics are disclosed in the provided filing information.

27-02-2026

Delek Logistics Partners, LP filed an 8-K on 2026-02-27 disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet impacts, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.

27-02-2026

Delek US Holdings, Inc. filed an 8-K on 2026-02-27 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item voluntary disclosure pertains to financial results. No quantitative metrics, period-over-period comparisons, guidance, or other specific financial details are disclosed.

27-02-2026

Fulgent Genetics, Inc. filed a Form 8-K on February 27, 2026 (AccNo: 0001193125-26-079152), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results, but specific revenue, earnings, balance sheet details, guidance, or performance metrics are NOT_DISCLOSED. No positive, negative, or flat metrics, period-over-period comparisons, or other quantitative data are provided in the filing summary.

27-02-2026

NIQ Global Intelligence plc filed a Form 8-K on 2026-02-27 under Item 2.02 announcing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, guidance, period-over-period changes, or other quantitative metrics are disclosed in the filing summary. This is a standard voluntary earnings-related disclosure without detailed financial data provided.

27-02-2026

TechTarget, Inc. filed an 8-K on February 27, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The filing also includes Item 7.01 for Regulation FD disclosure and Item 9.01 for financial statements and exhibits. Specific details including key positions affected, names, appointment or resignation status, reasons, timing, and any quantitative data are NOT_DISCLOSED.

27-02-2026

Alpha Metallurgical Resources, Inc. filed an 8-K on February 27, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely involving voluntary disclosure of material non-public information with attached exhibits such as press releases or presentations. No specific financial metrics, transaction details, guidance, or quantitative data are disclosed in the filing summary.

27-02-2026

Alight, Inc. filed an 8-K on February 27, 2026 (AccNo: 0001193125-26-079261), disclosing an event under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Specific details including the key position affected, individual names, appointment or resignation status, reasons for change, and any compensatory arrangements are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or market impacts are mentioned.

27-02-2026

Calumet, Inc. /DE filed an 8-K on 2026-02-27 disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a standard financial results announcement, but specific revenue, earnings, guidance, or period-over-period comparisons are NOT_DISCLOSED in the provided filing details. No positive or negative metrics, transaction values, or operational changes were detailed.

27-02-2026

Globalstar, Inc. filed an 8-K on February 27, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance changes were disclosed in the provided filing information. No positive, negative, or flat metrics were mentioned.

27-02-2026

United States Commodity Index Funds Trust filed an 8-K on February 27, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific events, transactions, financial metrics, or quantitative data are detailed in the filing summary provided. This appears to be a multi-item voluntary disclosure with attached exhibits.

27-02-2026

GLOBAL PARTNERS LP filed an 8-K on February 27, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results, but specific revenue, earnings, guidance, or period-over-period comparisons are NOT_DISCLOSED in the provided filing details. No positive or negative metrics are explicitly stated.

27-02-2026

Enzon Pharmaceuticals, Inc. filed a Form 8-K on 2026-02-27 reporting entry into a material definitive agreement under Item 1.01 (potential strategic positive) but also material modifications to rights of security holders under Item 3.03 (potential negative for shareholders), alongside Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). This is a multi-item filing with no specific transaction details, dollar values, or financial metrics disclosed. No positive or negative quantitative changes are mentioned.

27-02-2026

reAlpha Tech Corp. filed an 8-K on 2026-02-27 disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule under Item 3.01, alongside Departure of Directors or Certain Officers under Item 5.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This multi-item filing signals a major negative development with delisting, which typically impairs liquidity and investor access, compounded by potential leadership changes. No quantitative financial metrics, transaction values, or period-over-period comparisons are disclosed.

27-02-2026

International Endeavors Corp filed an 8-K on 2026-02-27 under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure, financial statements, or exhibits are provided. No quantitative metrics, events, or impacts are disclosed.

27-02-2026

MGE Energy Inc filed an 8-K on February 27, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core events, transactions, financial metrics, or period-over-period comparisons are disclosed in the filing summary. Critical details such as dollar values, guidance, or scheduled events are not provided.

27-02-2026

Ohio Valley Banc Corp filed an 8-K on February 27, 2026 (AccNo: 0000894671-26-000021, Size: 149 KB), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Specific details including the key position affected, individuals involved, appointment or resignation status, reasons for change, and any governance or financial impacts are NOT_DISCLOSED. No quantitative metrics, scheduled events, or other financial data are mentioned in the provided filing information.

27-02-2026

DEERE & CO filed an 8-K on February 27, 2026, specifically under Item 5.07, reporting the submission of matters to a vote of security holders. This disclosure pertains to the results of a shareholder vote, typically from an annual or special meeting, but no specific proposals, vote tallies, or outcomes are detailed in the provided filing summary. No financial metrics, changes, or other quantitative data are mentioned.

27-02-2026

BancFirst Corp (/OK/) filed an 8-K on 2026-02-27 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Regulation FD Disclosure under Item 7.01. Specific details including the key position affected, whether it is an appointment or resignation, internal/external status, reason, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

27-02-2026

Sphere 3D Corp. (NASDAQ: ANY) received notice from Nasdaq on February 26, 2026, confirming it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This resolves the deficiency initially notified on March 6, 2025. No further actions or ongoing issues related to this rule are mentioned.

• ·Registrant's principal executive offices: 243 Tresser Blvd, 17th Floor, Stamford, Connecticut, United States 06901
• ·Telephone number: (647) 952 5049
• ·IRS Employer Identification No.: 98-1220792
• ·Commission File Number: 001-36532

27-02-2026

Texas Capital Bancshares, Inc. completed a public offering of $400M aggregate principal amount of 5.301% Fixed-to-Floating Rate Senior Notes due February 27, 2032, receiving $398.4M in proceeds before offering expenses. The company intends to use the net proceeds for general corporate purposes, which may include funding the redemption of its 4.000% Subordinated Notes due 2031. The notes bear a fixed interest rate of 5.301% payable semi-annually until February 27, 2031, then transition to a floating rate based on Compounded SOFR plus 1.94% payable quarterly.

• ·Underwriting agreement dated February 24, 2026, with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and TCBI Securities, Inc. as representatives.
• ·Indenture dated February 27, 2026, with U.S. Bank Trust Company, National Association as trustee.
• ·Offering pursuant to Registration Statement No. 333-277061 filed February 14, 2024, and Prospectus Supplement dated February 24, 2026.
• ·Date of earliest event reported: February 24, 2026; Filing date: February 27, 2026.

27-02-2026

Xenon Pharmaceuticals Inc. filed a prospectus supplement on February 27, 2026, to register $400M of common shares issuable under its at-the-market equity offering sales agreement with Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, dated August 6, 2020, and amended March 1, 2022. As of the filing date, the company has sold $291.1M in shares under the sales agreement and prior prospectus, which has now been terminated and replaced by the new supplement. No shares have been sold under the new prospectus as of the report date.

• ·Sales agreement originally dated August 6, 2020, and amended on March 1, 2022.
• ·Registration statement on Form S-3 (File No. 333-281451) filed August 9, 2024, with base prospectus dated same day.
• ·Legal opinion on shares provided as Exhibit 5.1 by Blake, Cassels & Graydon LLP.

27-02-2026

On February 26, 2026, the Compensation Committee of Iridium Communications Inc. approved the Annual Performance Bonus Plan, making eligible employees including CEO, CFO, and other NEOs eligible for cash or RSU bonuses up to 200% of target based on corporate and individual performance goals for periods starting January 1, 2026. The Committee also adopted the Executive Severance Plan, providing non-CIC severance of 18 months base salary (CEO) or 12 months (other NEOs) plus prorated bonus and COBRA, with enhanced CIC benefits including 2X (CEO) or 1.5X (others) of base plus target bonus and full equity vesting acceleration. These plans are subject to recoupment under the Company's Incentive Compensation Recoupment Policy and will be filed as exhibits to the Q1 2026 10-Q.

• ·Non-CIC severance includes prorated annual target bonus and COBRA premiums for up to 12 months.
• ·CIC severance paid in lump sum with full acceleration of outstanding equity awards.
• ·Plans require execution of waiver/release and compliance with restrictive covenants.

27-02-2026

Northpointe Bancshares, Inc. (NYSE: NPB) announced the appointment of Rodney E. Hood, former Acting Comptroller of the Currency and Chairman of the National Credit Union Administration (NCUA), to the Board of Directors of the Company and its subsidiary Northpointe Bank, effective February 27, 2026. Hood brings nearly three decades of financial services leadership, including roles at the FDIC, FSOC, and FFIEC, to support strategic growth, governance, and risk management. Chairman and CEO Chuck Williams highlighted Hood's expertise in innovation and community value, aligning with the company's focus as a leading mortgage warehouse financing provider.

• ·Headquartered in Grand Rapids, Michigan.
• ·Contacts: Kevin Comps (616-974-8491), Brad Howes (616-726-2585).

27-02-2026

Avis Budget Group, Inc. shareholders are notified of proposed voluntary dismissals, subject to court approval, of two shareholder derivative actions filed in 2025 alleging breaches of fiduciary duties and misleading statements related to the company's February 2025 announcement of accelerated fleet rotation and a non-cash impairment for Q4 2024. The actions, Jones v. Pahwa (filed June 6, 2025) and Dua v. Ferraro (filed September 9, 2025), seek unspecified damages and governance changes but are set to be dismissed without prejudice unless another shareholder intervenes by April 13, 2026.

• ·Court ordered notice on November 24, 2025.
• ·Case numbers: Jones v. Pahwa, No. 2:25-cv-07934-MEF-CF; Dua v. Ferraro, No. 2:25-cv-15382-MEF-CF.
• ·Intervention motions due by April 13, 2026, to Clerk of U.S. District Court for the District of New Jersey, 50 Walnut Street, Room 4015, Newark, NJ 07101.
• ·Complaints available at specified URLs.

27-02-2026

Triumph Financial, Inc. (NYSE: TFIN) declared a quarterly cash dividend of $17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock, equivalent to $0.44525 per depositary share (NYSE: TFIN-PR). The dividend is payable on March 30, 2026, to holders of record at the close of business on March 15, 2026. No period-over-period comparisons or other financial metrics were provided in the announcement.

• ·Triumph is headquartered in Dallas, Texas.
• ·Company's Annual Report on Form 10-K filed with SEC on February 11, 2026.
• ·Investor Relations: lwyse@tfin.com, 214-365-6936; Media: atavackoli@tfin.com, 214-365-6930.

27-02-2026

Pathfinder Bancorp, Inc. revised its Q4 2025 net loss to $5.6M or $(0.88) per diluted share from the previously reported $7.0M or $(1.11) per share, due to an additional $1.5M non-cash income tax benefit, increasing the Q4 tax benefit to $3.0M. For the full year 2025, the net loss improved to $1.9M or $(0.31) per diluted share from $3.4M or $(0.54) per share, with the annual tax benefit revised to $2.2M. Despite these improvements, the company continues to report net losses for both the quarter and the year.

• ·The $1.5M income tax adjustment is non-cash and reflects updated deferred tax asset analysis as of December 31, 2025.
• ·Corrected financials will be in forthcoming Form 10-K.
• ·Original earnings press release issued January 29, 2026.

27-02-2026

FirstSun Capital Bancorp held a special shareholder meeting on February 27, 2026, where stockholders overwhelmingly approved three key proposals related to its merger with First Foundation Inc., including adoption of the merger agreement dated October 27, 2025, an increase in authorized common stock shares, and creation of a new class of non-voting common stock. Proposal 1 (merger approval) passed with 24,390,817 votes for, 21,071 against, 98,685 abstentions, and 485,766 broker non-votes. All proposals received strong support with no significant opposition.

• ·Definitive joint proxy statement/prospectus filed January 15, 2026, supplemented February 6, 2026.
• ·Proposal 4 (adjournment) withdrawn as not needed due to quorum and approvals.
• ·Merger agreement dated October 27, 2025.

27-02-2026

Advanced Drainage Systems, Inc. entered into a Fourth Amendment to its Credit Agreement on February 27, 2026, refinancing in full its existing term loans with new 2026 Refinancing Term Loans equal to the outstanding principal and replacing existing revolving commitments with new 2026 Refinancing Revolving Commitments plus incremental commitments to achieve a total revolving facility of $750M. The amendment also includes $192M in new 2026 Incremental Term Loans and replaces Barclays Bank PLC with PNC Bank, National Association as administrative agent. No performance declines noted, but the transactions increase overall debt capacity.

• ·Refinancing matches aggregate principal of existing term loans and revolving commitments outstanding prior to amendment.
• ·Bank of America, N.A. designated as Term Administrative Agent.
• ·PNC Capital Markets LLC, Bank of America, N.A., and others act as joint lead arrangers and bookrunners.

27-02-2026

GE HealthCare Technologies Inc. entered into a 364-day revolving credit agreement dated February 26, 2026, providing a $500M revolving credit facility to enhance liquidity. JPMorgan Chase Bank, N.A. serves as administrative agent, with Citibank, N.A., BofA Securities, Inc., BNP Paribas Securities Corp., Goldman Sachs Bank USA, and Morgan Stanley Senior Funding, Inc. as joint bookrunners and lead arrangers. No performance metrics or comparisons are provided in the filing.

• ·Facility includes ABR Loans denominated in Dollars and Term Benchmark Borrowings in Agreed Currencies (Dollars, Euros, Sterling).
• ·Availability Period: from Closing Date to earlier of Final Maturity Date or termination of Commitments.

27-02-2026

Gentherm Incorporated and its subsidiaries entered into the First Amendment to the Second Amended and Restated Credit Agreement on February 24, 2026, amending provisions of the original June 10, 2022 agreement and adding a new Pari Passu Intercreditor Agreement exhibit. The amendment facilitates releases of certain borrowers and guarantors, including Gentherm Enterprises GmbH, Gentherm Licensing GmbH, Gentherm Licensing Limited Partnership (via mergers/dissolution), Gentherm Holding (Malta) Limited, Gentherm Automotive Systems (Malta) Limited (planned liquidation), and Gentherm Properties I, LLC (dissolved), with remaining obligations assumed by other loan parties. No changes to overall borrowing capacity or financial terms were specified.

• ·Original Credit Agreement dated June 10, 2022.
• ·Maltese Release letter agreement dated October 10, 2025.
• ·Administrative Agent to execute release documents at Company's expense.

27-02-2026

Whirlpool Corporation announced concurrent public offerings of common stock and depositary shares (each 1/20th interest in Series A Mandatory Convertible Preferred Stock), anticipating $800M in aggregate proceeds to repay revolving credit facility debt and fund general corporate purposes, including strategic investments in vertical integration and automation. The Preferred Stock carries a $1,000 liquidation preference per share and automatically converts into common stock around February 15, 2029. In 2025, Whirlpool reported approximately $16B in annual net sales (close to 90% in the Americas), 41,000 employees, and 35 manufacturing and technology research centers.

• ·Underwriters grant 30-day overallotment option for additional Common Stock and Depositary Shares.
• ·Depositary Shares to be listed on NYSE under symbol 'WHR.PRA'.
• ·Announcement dated February 23, 2026; automatic conversion of Preferred Stock on or about February 15, 2029.

27-02-2026

VERAXA Biotech AG shareholders approved the merger with Veraxa Biotech Holding AG and an ordinary capital increase of up to CHF 223,400 at their EGM on February 27, 2026, advancing the business combination with Voyager Acquisition Corp. (NASDAQ: VACH). The approvals are prerequisites for closing, subject to Voyager shareholder approval, after which the combined entity will trade on NASDAQ under 'VRXA'. No financial performance metrics or declines were reported, highlighting progress without disclosed setbacks.

• ·Business Combination Agreement signed on April 22, 2025.
• ·Proxy statement/prospectus filed with SEC on February 19, 2026.
• ·Merger via absorption: Veraxa Biotech Holding AG acquires VERAXA and renames to Veraxa Biotech AG.

27-02-2026

Hashdex Nasdaq Crypto Index US ETF filed an 8-K disclosing Amendment #1 to its Authorized Participant Agreement with Virtu Americas LLC and sponsor Hashdex Asset Management Ltd., dated February 24, 2026. The amendment replaces the Procedures Handbook in full, updates the agreement summary, adds Section 16 for optional in-kind transactions using digital assets for Creation Unit creations/redemptions (minimum 10,000 Shares), and addresses regulatory changes, fees, taxes, and settlement procedures. No financial impacts or performance metrics are disclosed.

• ·Original Authorized Participant Agreement dated January 14, 2025.
• ·SEC Registration Statement No.: 333-280990.
• ·Purchase Order cut-off time: 3:00 P.M. Eastern.
• ·Standard settlement: T+1 business day following purchase order date.

27-02-2026

Jewett-Cameron Trading Company Ltd. held its Annual General Meeting on February 27, 2026, where shareholders approved receipt of financial statements for the fiscal year ended August 31, 2025, fixed the board at five directors, elected Charles E. Hopewell, Michelle Walker, Chad Summers, Subriana Pierce, and Ian Wendler as directors, appointed auditors, ratified directors' and officers' acts, and approved executive compensation on an advisory basis. However, several proposals faced significant opposition, including acts and deeds of directors/officers (525,764 shares against out of ~1.66M voted), advisory vote on executive compensation (611,957 against), and transacting other business (666,212 against). All items ultimately passed despite the mixed support.

• ·Item 1 (financial statements and auditor’s report) was duly adopted without specific vote counts provided.
• ·Hopewell received the lowest For votes among directors (1,027,692) and highest withheld (629,290).
• ·Non-votes ranged from 0 to 553,295 across items.

27-02-2026

Mechanics Bancorp announced the adoption of Amended and Restated Bylaws effective February 25, 2026, via an 8-K filing on February 27, 2026, covering Items 5.03, 8.01, and 9.01. The bylaws detail governance procedures for shareholder meetings (annual and special, with special meetings callable by the Board, Chair, President, Secretary, or shareholders holding at least 10% of voting shares), board of directors, officers, shares, indemnification, and forum selection. No financial metrics, changes, or impacts are disclosed.

• ·Special meeting requests require a proper form initial request for Requested Record Date, followed by requests from shareholders holding the Requisite Percentage (10%) within 60 days.
• ·Business at special meetings limited to Proposed Business in valid requests, notice, or Board/chair direction.
• ·Detailed shareholder notice requirements under Section 1.12, including questionnaires, representations, and director nominee eligibility.

27-02-2026

IP Strategy Holdings, Inc. (IPST) reported preliminary Q4 2025 net revenues of $4.6-4.8M, up ~53-60% QoQ from $3.0M in Q3, and full-year 2025 revenues of $9.8-10.3M, up ~17-23% YoY from $8.4M in 2024, driven by validator operations at >95% gross margins. However, Q4 net loss before taxes swung to $380-384M from Q3 profit of $245.7M, and full-year loss reached $146.5-148.5M from 2024 profit of $0.7M, primarily due to $126.5-129.5M mark-to-market loss on 53.2M $IP Tokens amid a price drop from $8.54 to $1.732. Restructuring closed retail tasting rooms with $3.2-3.6M write-downs but eliminated $19.3M debt (saving >$2M annual interest) and >$5M annual op ex from 2026, net of ~$3.5M revenue loss.

• ·$IP Tokens acquired at average basis of $3.93 per token
• ·Q4 2025 third-party staking fees: 40,595 $IP Tokens
• ·Annual interest expense savings >$2M; op ex savings >$5M from 2026 (net of ~$3.5M revenue loss)

27-02-2026

Landmark Bancorp, Inc. selected Forvis Mazars, LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, following a competitive process by the Audit Committee, with Crowe LLP dismissed effective after completing the 2025 audits. There were no disagreements or reportable events with Crowe during fiscal years 2024 and 2025, and Crowe's audit reports were unqualified. Crowe provided a letter dated February 27, 2026, concurring with the disclosures.

• ·Crowe’s audit reports on consolidated financial statements for fiscal years ended December 31, 2024 and 2025 did not contain adverse opinions, disclaimers, or qualifications as to uncertainty, audit scope, or accounting principles.
• ·No prior consultations with Forvis Mazars on accounting principles, audit opinions, or related matters before retention.
• ·Forvis Mazars engagement begins with review of Q1 2026 quarterly consolidated financial statements, subject to client acceptance procedures.

27-02-2026

On February 24, 2026, Ambarella Inc.'s Compensation Committee approved the Fiscal Year 2027 Annual Bonus Plan (FY2027 Bonus Plan), featuring an aggregate target bonus pool approximately 28% larger than the FY2026 plan. CEO Feng-Ming Wang is eligible for a 100% bonus target of his base salary, with other executives (John Young, Chan Lee, John Ju, Yun-Lung Chen) ranging from 40% to 75%; payouts are weighted 1/3 each on revenue, operating profit, and non-financial objectives, with a maximum of 167% of target. No threshold performance results in zero funding, and payouts require continued employment.

• ·Compensation Committee and Board have discretion to adjust bonus pool size and individual payouts.
• ·Payouts to be made no later than two and one-half months after end of FY2027.
• ·Performance between threshold and target uses linear interpolation.

27-02-2026

Flagstar Bank, N.A. (NYSE: FLG) announced its 2026 Annual Meeting of Shareholders on June 9, 2026, at 10:00 a.m. ET in a virtual format, with a record date of April 10, 2026; proxy materials will be filed with the OCC and SEC. As of December 31, 2025, the Bank reported $87.5B in assets, $61.0B in loans, $66.0B in deposits, and $8.1B in stockholders' equity, while operating approximately 340 locations across ten states. The release includes cautionary forward-looking statements referencing prior events like the October 2025 reorganization and no new performance metrics.

• ·Bank headquartered at 102 Duffy Avenue, Hicksville, NY 11801.
• ·Operates with strong footholds in greater New York/New Jersey, upper Midwest, Florida, and West Coast.

27-02-2026

OpGen, Inc. (OTC: OPGN) announced its name change to CapForce Inc., effective February 27, 2026, to reflect a repositioning toward digital investment banking and fintech services targeting high-growth mid-sized companies with $1B-$10B market caps. The company plans to change its ticker to 'CFOR' and is developing a digital platform with AI-powered robo-advisory and cap table management, subject to market and regulatory factors; its controlling shareholder AEI Capital Group manages over $7B in AUM. Forward-looking statements highlight risks including rebranding costs, execution challenges, and potential customer/investor confusion.

• ·Name change effective February 27, 2026
• ·Expected ticker symbol change to 'CFOR'
• ·Subsidiaries: CapForce International Holdings Ltd. and iCapX Sdn. Bhd.
• ·AEI Capital Group footprints: Hong Kong, Kuala Lumpur, Singapore, London, Washington D.C.

27-02-2026

On February 27, 2026, Bridgewater Bancshares, Inc. and its subsidiary Bridgewater Bank entered into an Equity Distribution Agreement with Piper Sandler & Co. to issue and sell up to $50 million of common stock through at-the-market offerings. The agreement allows sales via various methods, with the company paying a 2.5% commission on gross sales prices; there is no obligation to sell any shares, and either party may terminate at any time. Net proceeds, if any, will support general corporate purposes such as subsidiary investments, working capital, capital expenditures, stock repurchases, debt repayment, or acquisitions.

• ·Sales under the agreement will be made pursuant to shelf registration statement Form S-3 (No. 333-284662), effective February 10, 2025, with prospectus supplement filed February 27, 2026.
• ·Agreement includes customary representations, warranties, covenants, indemnification, and expense reimbursements.